Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1Phase 1/2 1

Status

Unknown 1Completed 1Active not recruiting 1

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

Head & Neck 3Gastrointestinal 1

Conditions

Carcinoma, Non-Small-Cell Lung 57Breast Neoplasms 35Neoplasms 32Parkinson Disease 4, Autosomal Dominant Lewy Body 25Multiple Myeloma 24Leukemia, Myeloid, Acute 21Recurrence 20Colorectal Neoplasms 17Neoplasm Metastasis 17Lymphoma, Non-Hodgkin 15Ovarian Neoplasms 15Carcinoma, Renal Cell 14Leukemia 14Leukemia, Lymphocytic, Chronic, B-Cell 14Melanoma 14Lymphoma, Follicular 12Precursor Cell Lymphoblastic Leukemia-Lymphoma 12Lung Neoplasms 11Myelodysplastic Syndromes 11Urinary Bladder Neoplasms 11Carcinoma, Hepatocellular 10Hematologic Neoplasms 10Leukemia, Myelogenous, Chronic, BCR-ABL Positive 10Adenocarcinoma 9Glioma 9Lymphoma 9Lymphoma, Large B-Cell, Diffuse 9Lymphoma, Mantle-Cell 9Prostatic Neoplasms 9Stomach Neoplasms 9

Interventions

toripalimab 1penpulimab 1Gemcitabine 1Cisplatin 1Carboplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Has announcements × Nasopharyngeal Carcinoma × Clear all
NCT04974398 2025-04-13

A Study of Penpulimab (AK105) in the First-line Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma

Akeso

Phase 3 Active not recruiting
296 enrolled 1 FDA
Head & Neck

Nasopharyngeal Carcinoma

NCT03866967 2025-02-27

A Study of Anti-PD-1 AK105 in Patients With Metastatic Nasopharyngeal Carcinoma

Akeso

Phase 2 Completed
130 enrolled 1 FDA
Head & Neck

Nasopharyngeal Carcinoma

NCT02915432 2021-12-13

The Study to Evaluate Toripalimab (JS001) in Patients With Advanced GC, ESCC, NPC, HNSCC

Shanghai Junshi Bioscience Co., Ltd.

Phase 1/2 Unknown
401 enrolled 1 FDA
GastrointestinalHead & Neck

Squamous Cell Carcinoma of Head and Neck, Nasopharyngeal Carcinoma, Esophageal Squamous Cell Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡